The AMT, Accuron and Tianda Pharmaceuticals-backed cancer drug developer raised half of its initial target for the offering.
Singapore-based oncology therapy developer Aslan Pharmaceuticals, which counts corporates Accuron, Tianda Pharmaceuticals and Advanced Materials Technologies (AMT) as investors, has raised $42.2m in an initial public offering in the US.
Aslan priced 6 million American Depositary Shares, each representing five common shares, at $7.03 each last week. The IPO’s underwriters have the 30-day option to buy another 900,000 ADSs, which would increase the size of the offering to approximately $48.6m.
Aslan is working on treatments for orphan diseases in…
